chrisvoncsefalvay/vaers-outcomes huggingface dataset:
significant shoulder/neck stiffness; headache; raised red rash on stomach and chest, not really itchy/Rash still here am; raised red rash on stomach and chest, not really itchy; muscle soreness and headache back to mild; raised red rash on stomach and chest, not really itchy/Rash still here am; This is a spontaneous report from a contactable other hcp (Nurse) (patient). A 48-year-old (non-pregnant) female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VAC-CINE, Solution for injection, Batch/Lot Number: ER2613) via an unspecified route of administration, administered in arm left on 06Apr2021 08:45 (at the age of 48-year-old) at dose 2, single for covid-19 immunisation. Medical history included hypothyroid and allergies to sesame seeds, severe abd pain, allergy verified by blood test, chia seeds anaphylaxis. Latex rash and allergy verified by blood test. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. Concomitant medications included levothyroxine (LEVOTHY-ROXINE); lysine (LYSINE); vitamin d [vitamin d nos] (VITAMIN D [VITAMIN D NOS]); vitamins nos (MULTIVITAMIN [VITAMINS NOS]), all taken for an unspecified indication, start and stop date were not reported, patient received these medications within 2 weeks of vaccination. Patient historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EN6200) via an unspecified route of administration, administered in arm left on 16Mar2021 08:45 (at the age of 48-year-old) at dose 1, single for covid-19 immunisation after 1st dose patient experienced mild shoulder/neck stiffness, arm sore, not bad. On 07Apr2021 19:00 the patient experienced adverse event after 2nd dose significant shoulder/neck stiffness, headache and eve of 4/7 raised red rash on stomach and chest, not really itchy. Rash still here am of 4/8/21 but muscle soreness and headache back to mild. The patient underwent lab tests and procedures which included blood test: allergy on an unspecified date (allergy verified by blood test). Patient did not received treatment for the adverse events. Outcome of the events was resolving. No follow-up attempts are needed. No further information is expected.
hingles  vaccine was on Friday 8/23. Patient reported about 3 hours after the vaccine he  began to have muscle and joint pain, 103 fever and a pounding headache. Patient  reports the symptoms have disappeared since last night 8/25.
Soreness in right arm where I received the Pneumonia shot arm started to become more intense.... By 7:00 PM arm was red and swollen-very sore. By 11:00 pm upper arm very swollen, red, hot. Could not lift or touch without intense pain. Took Aleve medication. Arm still swollen and red in AM the following day but pain somewhat less. Took more Aleve, called Primary Care Physician who said to apply cold pack and continue with Aleve. It is now 8:30 PM. Pain has lessened considerably but upper arm still sensitive, swollen and red although much of swelling has been reduced.
Real bad headache; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Real bad headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Real bad headache). At the time of the report, HEADACHE (Real bad headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication- (not clear) for headache was reported. No concomitant medications were reported.
Patient's daughter called and said her mother's arm was red and swollen from the shot she received.  I checked with her again today and she states her mother's arm is not as red but still has a "knot" and it's hot and a little swollen.
Red area around injection site, a little swollen, and warm. This occurred 11 days after the vaccination.
very swollen, large softball size red around shot, chills, next day cold symptoms, 3nd day cough and short of breath, 4th day aches, flu symptoms, feels like I have covid  AGAIN!! took advil,  2nd day cough medicine,  3rd day flue medicine, drank lots of liquid...symptoms still prevalent and very tired at end of 5th day .  I have called Dr office, they do not think it is related to shot. I told them I have had covid, they said it was fine to get the shot 3 months after...it obviously was not. My Dr cannot see me until DECEMBER
chills/fever 23JAN93; 1/2" x 3" reddness, warm, swollen area w/central vesiculation of each deltoid rt & lt;
sick for a week; diarrhea; nauseous; 106 degree fever; second booster was administered inappropriately and was not giving in the deltoid muscle; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (sick for a week), DIARRHOEA (diarrhea), NAUSEA (nauseous), PYREXIA (106 degree fever) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (second booster was administered inappropriately and was not giving in the deltoid muscle) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes.    On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced ILLNESS (sick for a week), DIARRHOEA (diarrhea), NAUSEA (nauseous), PYREXIA (106 degree fever) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (second booster was administered inappropriately and was not giving in the deltoid muscle). At the time of the report, ILLNESS (sick for a week) had resolved and DIARRHOEA (diarrhea), NAUSEA (nauseous), PYREXIA (106 degree fever) and INCORRECT ROUTE OF PRODUCT ADMINISTRATION (second booster was administered inappropriately and was not giving in the deltoid muscle) outcome was unknown.            No concomitant and treatment medications were reported by the reporter. Patient has since read that it may have cause her vaccine to fail. Patient would like to know if that was true and if she needs to get another. Patient has spoken to the pharmacist that the technician gave it in the wrong location. Patient did not think the vaccination provider was going to call us about the error. Patient had the first three shots (including the booster) and never had one side effect but after getting this second booster dose she experiencing 106 degree fever, diarrhea, nauseous, sick for a week.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 02-May-2022: Source Document contains non-significant information.
Pt experienced chronic fatigue, muscle pain entire body, spinal column hard, inflamed. Skin on back, arms, legs and neck very thick (hard). Numbness in feet and hands, heavy legs. Very strange mucous coming from lungs, very thick, shortness of breath. Possible Guillain Barre syndrome. Annual follow up states patient still has muscle weakness, fatigue, and inflammation in arms and legs.
generally lethargic; non productive cough; runny nose; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of LETHARGY (generally lethargic), COUGH (non productive cough) and RHINORRHOEA (runny nose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040A21A and 006M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Apr-2021, the patient experienced LETHARGY (generally lethargic), COUGH (non productive cough) and RHINORRHOEA (runny nose). At the time of the report, LETHARGY (generally lethargic), COUGH (non productive cough) and RHINORRHOEA (runny nose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Apr-2021, Oxygen saturation: other (Low) other. On 28-Apr-2021, SARS-CoV-2 test: other (Negative) other.         No concomitant medication were reported. No treatment was received.   Most recent FOLLOW-UP information incorporated above includes: On 20-Jun-2021: Email received on 21/6/2021 does not contain any new information
Leukocytosis, Weakness/Difficulty Walking, Altered Mental Status, Loss of Appetite, Redness and Swelling Site of Injection.
lymph nodes in the left axilla; This is a spontaneous report from a contactable consumer, the patient. A 19-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 10May2021 at 10:30 (at the age of 19-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. The patient did not receive any medication within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 17Apr2021 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11May2021, the patient experienced lymph nodes in the left axilla. The event resulted in doctor or other healthcare professional office/clinic visit. It was unknown if any therapeutic measures were taken as a result of the event. The clinical outcome of the event lymph nodes in the left axilla was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Febrile seizure on 10/31/06 with emergency room follow up visit on 11/01/06. Chart notes from office visit attached. Emergency room report attached. Patient apparently has been fussy all day with probable fever although mother has not checked it. As she was being held in mother's arms this afternoon approximately an hour prior to arrival mother noticed that eyes rolled back in head, became rigid and was not breathing well. Her lips became blue. This lasted for 20-30seconds and then she became limp. Paramedics arrived. She was a bit lethargic at that point. Axillary temp is 103.7. Vital signs were otherwise stable. She was transported to this facility. Has not had any cough for URI symptoms, no nausea or vomiting, no diarrhea.
Jynneos vaccine was drawn up into the syringe one hour before it was administrated to the patient.; Jynneos vaccine was drawn up into the syringe one hour before it was administrated to the patient.; Case reference number US-BN-2022-002245 is a spontaneous case report initially received on 01-Sep-2022 from a pharmacist via Communications (reference number: USBAV22-1249), and concerns a patient of unknown age and gender.  The patient's medical history and concomitant medication details were not reported.  On an unspecified date, the patient received the Jynneos vaccine (Smallpox and Monkeypox Vaccine, Live, Nonreplicating; batch number: unknown)  that was drawn up into the syringe one hour before the administration, at an unknown dose, route, or site of administration, for smallpox/ monkeypox (explicitly coded as ' Product storage error', 'Product administration error ').  At the time of this report, it was unknown which dose this was, or whether the patient experienced any adverse events due to Jynneos.  Additional information received on 05-Sep-2022 from Bavarian Nordic included local BN case ID.  This case is linked with US-BN-2022-002246 and US-BN-2022-002247 concerning the same reporter; Reporter's Comments: On an unspecified date, a patient of unknown age and gender received the Jynneos vaccine that was drawn up into the syringe one hour before the administration, for smallpox/monkeypox, which is considered as product storage error and product administration error. No associated adverse events were reported. Product storage error and product administration error are listed per company convention. The patient's medical history and concomitant medication details were not reported. Product storage error and product administration error are not related to Jynneos, but to a human factor. The case is non-serious.; Sender's Comments: On an unspecified date, a patient of unknown age and gender received the Jynneos vaccine that was drawn up into the syringe one hour before the administration, for smallpox/monkeypox, which is considered as product storage error and product administration error. No associated adverse events were reported. Product storage error and product administration error are listed per company convention. The patient's medical history and concomitant medication details were not reported. Product storage error and product administration error are not related to Jynneos, but to a human factor. The case is non-serious.
Erythematous macular eruption on trunk and extremities began without 24 hours of vaccination.  Modest pruritus.  NO fever, chills, pain, vesicles, myalgia or other associated symptoms
Rash on neck and chest area. Very itchy, red, swelling. Still ongoing after 3 weeks.
Numbness/cold in legs.  Numbness in arm and one finger of vaccinated arm.  Tightness of throat and upper back pain.
This spontaneous report was received from a 45 year old female patient with polycystic ovarian syndrome regarding herself. No drug reactions were reported. The patient had mentioned that she was administered with GARDASIL (lot#, expiry not reported) 0.50mL, dose 1 on 15-AUG-2013 and dose number 2 on 21-OCT-2013. No concomitant medications were reported. The patient had confirmed that she had indeed received 2 shots. The patient would call her health care provider and get back on the dates of the injections. The patient's third shot was due in 15-FEB-2014. The patient had reported that GARDASIL had given her some wonderful side effects. She stated that the reason she was getting the vaccine, was because she was sure that she had human papillomavirus (HPV). She had a lesion on her thigh that she thought was caused by a type of HPV. Two of her physicians had told her that this lesion was either a skin tag or a mole. Before getting the shots, she has felt something moving around and all over her body. The patient could not pinpoint what that something would be and it was very painful at times. Immediately after getting the first injection (that night), her anxiety levels decreased and with each subsequent injection, her anxiety continued to go down. The injections relaxed her. The something that had been moving around in her body, had decreased in pain intensity and occurred less frequently. The patient had called back again to inform that she had the tell tale symptoms of HPV, such as an unspecified lesion. However she stated also that she had tremendous relief since getting the first 2 GARDASIL shots. Before the first injection, she had a feeling of stinging pain going through her body. After the first shot, the feeling left, but then resurfaced soon before getting the second dose. The patient said that GARDASIL should be given in higher doses because it might not be strong enough (details not specified). The patient also reported having a hip disability, onset date unknown. The patient had stated on another call, that each time she received a GARDASIL injection it seemed to suppress her HPV symptoms. The patient has suggested that the manufacturer should conduct a study for the vaccine to be used as a treatment for HPV. The patient had volunteered to be a part of this initiative and also suggested that for the study of the vaccine used as a course of treatment the vaccine should be given in higher doses and for a longer dosing regimen above the 3 shot series. A PAP test was performed (results not reported). Patient sought medical attention saw several physicians. The outcome of events hip disability was unknown. Reporter's causality was not provided. Upon internal review, the seriousness criterion of event hip disability was considered to be disability. Additional information has been requested.
during 30 min observation period, patient developed swelling of lips and chest tightness.  given diphenhydramine 50mg.  Felt better.
A serious increase in the frequency of heartburn; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of DYSPEPSIA (A serious increase in the frequency of heartburn) and NAUSEA (Nausea) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DYSPEPSIA (A serious increase in the frequency of heartburn) and NAUSEA (Nausea). At the time of the report, DYSPEPSIA (A serious increase in the frequency of heartburn) and NAUSEA (Nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment medications were reported.   Reporter did not allow further contact
Lethargy, slept 24-36 hours after shot. Was arrousable but would go back into deep sleep. Decreased eating secondary to sleep.
looked more like a rash, eczema rash around her eye; eye itchy; This spontaneous case was reported by a consumer and describes the occurrence of EYE PRURITUS (eye itchy) and ECZEMA (looked more like a rash, eczema rash around her eye) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jan-2021, the patient experienced EYE PRURITUS (eye itchy). On 15-Jan-2021, the patient experienced ECZEMA (looked more like a rash, eczema rash around her eye). At the time of the report, EYE PRURITUS (eye itchy) and ECZEMA (looked more like a rash, eczema rash around her eye) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded
This spontaneous report as received from a pharmacist refers to two patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. On unknown dates, the patients were inadvertently vaccinated with the expired doses of PNEUMOVAX 23 (lot # J005071, expiration date 19-JAN-2015; dose and route of administration were not reported). No adverse effects were reported. Follow up information was received via phone call on 19-DEC-2016 and indicated that all telephone attempts to obtain follow up information had been unsuccessful. Follow up information was received via phone call on 19-DEC-2016 from the pharmacist. The pharmacist stated that she had forwarded the correspondence to the pharmacist at the clinic where the adverse event occurred. The reporter stated that she would follow up with that pharmacist and have her fax the information in. On 21-DEC-2016, demographic information about one patient was received and it was reported that the patient was a 65-year-old female. This is one of two report received from the same reporter. Additional information is not expected, as all required correspondence has been received. Sender's Comments: US-009507513-1610USA009284.
Patient received Covid booster on 4/28. No issues until May 7th. Patient had a terrible pain in the top of his head. The pain traveled to his eyes causing blurred vision. Patient had to sit down, patient broke out in a sweat and lost all color. After sitting and resting patient was fine.
Severe rash, severe redness and swelling, blisters, peeling on her body. Ointment therapy. I have always suspected her ongoing severe skin issues were directly related to the vaccines. The skin issues never completely healed between each series of vaccinations but only gotten worse right after receiving her vaccinations. Each episode would take weeks to months before starting to subside, only to be triggered again by another round of vaccinations. I would discuss these medical issues with . Doctors at each visit and voice my concern that her medical issues were related to her vaccinations. However each doctor suggested a different possible cause and either provide a prescription or an ointment therapy to administer at home. I switch diaper brands. Tried different milk products and even removed all possible food allergens that her doctors would suggest. I switched soaps also. Nothing worked. To my astonishment and aggression no doctor did nor suggested allergy testing. I held off on filing any VAERS reports until we were able to get a doctor to agree to allergy testing to rule out an allergy.  Once she had the allergy testing and the results revealed no link to food allergies, we knew the only other possible cause were the vaccines.  This is why I'm reporting now.
High fever, severe head aches, sensitivity to light, sever stomach pain, abnormal liver functions, low white blood cell count, numbness in legs, dehydration.
Information has been received from a physician concerning a 12 year old male who on 24-MAY-1999 was vaccinated with a first dose of MMR II (route, site and lot number not reported). On 21-NOV-2003, the patient was vaccinated with a second dose of MMR II (route, site and lot number not reported). On 30-NOV-2009 the patient had fever 101 degrees F and left and "B" parotitis. The patient was diagnosed with mumps. The outcome for mumps was not reported. Follow up information has been received reporting that the 11 (previously reported as 12) year old male. On 29-DEC-2009 (previously reported as 30-DEC-2009). On 30-DEC-2009, the patient developed 101 degrees F of temperature, had vomit and developed left parotitis. At the time of the report, the patient's outcome was unknown. No further information is available.
This spontaneous report was received from a nurse, referring to patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with an intramuscular dose of GARDASIL 9 (strength, dose, and anatomical location were not reported) for prophylaxis. The valid lot number was N025428, with an expiry date of 19-JUN-2020. The dose of GARDASIL 9 vaccine was dispensed to the patient after it was exposed to a temperature excursion of 0.4 Celsius degrees, for 1 hour and 44 minutes. It was also reported that there was a data logger. This was the first temperature excursion for this product. No adverse effects were reported. No other information was available. No product quality complaint was filed.